Title: (capital letters) Moderator: (must have 1 moderator; please include name, degree(s), institution, city, state, country) Panelists: (must have 2-3 panelists; please include name, degree(s), institution, city, state, country)
Issue Panel purpose: (issue to be presented) Issue Panel overview: (background information should be included) |
IS NICE ALL THAT NASTY? COMPARISONS OF ACCESS TO CANCER THERAPY IN UK AND US HEALTH CARE |
Moderator: Lee N Newcomer MD, Senior Vice President, Oncology, UnitedHealthcare, Edina, MN, USA.
Panelist(s): Mike F Drummond PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, Heslington, UK; Scott Ramsey MD, PhD, Associate Member, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Dennis W Raisch PhD, Associate Center Director, Department of Veterans Affairs Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, USA
|
OVERVIEW: One of the concerns about the spread of health technology assessment in the United States is that it will lead to restrictions in access to approved therapies. The decisions of NICE in the UK are often cited as examples of the rationing of care that would be unpopular and perhaps unacceptable in the US. In this session, NICE guidance on new cancer therapies will be compared and contrasted with the corresponding formulary decisions of major public payers in the US. Specifically, we will discuss the timing of NICE guidance and US health insurer coverage decisions in relation to regulatory approval by each country's regulatory agency. In addition, the coverage rules and restrictions, if any, imposed on therapies for given indications, and trends in restrictions or openness in coverage will be compared. Ultimately, we address the question: Would the implementation of NICE guidance in the US negatively influence access to therapy for US cancer patients. |
